| Planet A Foods–Feast Ventures: investment, 202312c financing round Series A totalling €15.4m incl co-investor Feast Ventures |
2023-12-31 |
| Planet A Foods–Mudcake: investment, 202312c financing round Series A totalling €15.4m incl co-investor Mudcake |
2023-12-31 |
| Planet A Foods–Nucleus Capital: investment, 202312c financing round Series A totalling €15.4m incl co-investor Nucleus Capital |
2023-12-31 |
| Planet A Foods–Omnes Capital: investment, 202312c financing round Series A totalling €15.4m incl co-investor Omnes Capital |
2023-12-31 |
| Planet A Foods–SEVERAL: investment, 202312c financing round Series A €15.4m led by World Fund |
2023-12-31 |
| Planet A Foods–TriplePoint Capital: investment, 202312c financing round Series A totalling €15.4m incl co-investor TriplePoint Capital |
2023-12-31 |
| Planet A Foods–World Fund: investment, 202312c financing round Series A totalling €15.4m incl lead investor World Fund |
2023-12-31 |
| LumiraDx–Roche: investment, 202312– acquisition $295m + $55m milestones of parts of LumiraDx Group related to innovative PoC technology |
2023-12-29 |
| Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter |
2023-12-23 |
| Paion–Humanwell Healthcare: investment, 202312 acquisition of essential business operation of insolvent Paion AG + Paion Deutschland GmbH |
2023-12-22 |
| Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ |
2023-12-21 |
| Hookipa–Gilead: investment, 202312 equity investment $21.25m by Gilead with 15m shares at $1.42//share resulting in 19.4% shareholding of Gilead |
2023-12-20 |
| AC Immune–Avidity Partners: investment, 202312 underwritten offering totalling $50.05m incl co-investor Avidity Partners |
2023-12-15 |
| AC Immune–BVF Partners: investment, 202312 underwritten offering totalling $50.05m incl lead investor BVF Partners LP |
2023-12-15 |
| AC Immune–Redmile Group: investment, 202312 underwritten offering totalling $50.05m incl co-investor Redmile Group |
2023-12-15 |
| AC Immune–SEVERAL: investment, 202312 underwritten offering $50.05m led by BVF Partners with 14.3m common shares at $3.5/share |
2023-12-15 |
| AC Immune–StemPoint Capital: investment, 202312 underwritten offering totalling $50.05m incl co-investor StemPoint Capital LP |
2023-12-15 |
| MorphoSys–SEVERAL: investment, 202312 cash capital increase €102.7m with 3.42m new shares placed with institutional investors at €30/share |
2023-12-14 |
| Vandria–+ND Capital: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl lead investor +ND Capital |
2023-12-14 |
| Vandria–OTHER: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl small syndicate of HNW private investors |
2023-12-14 |
| Vandria–SEVERAL: investment, 202312 emerges from stealth with financing round Series A CHF18m led by +ND Capital |
2023-12-14 |
| Tome Biosciences–Bruker: investment, 202312 financing rounds Series A + B totalling $213m incl investor Bruker Corp |
2023-12-12 |
| Tome Biosciences–SEVERAL: investment, 202312 financing rounds Series A + B $213m announced at launch |
2023-12-12 |
| Zafrens–BY Capital: investment, 202312 company emerges with total of $23m in financing incl co-investor BluYard Capital |
2023-12-11 |
| Zafrens–SEVERAL: investment, 202312 company emerges with $23m in financing led by Prime Movers Lab |
2023-12-11 |
| Eligo Bioscience–Sanofi: investment, 202312 financing round Series B totalling $30m incl new + lead investor Sanofi Ventures |
2023-12-05 |
| Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures |
2023-12-05 |
| Odyssey Therapeutics–BlackMars Capital: investment, 202312 financing round Series C totalling $101m incl co-investor BlackMars Capital |
2023-12-05 |
| Odyssey Therapeutics–HBM: investment, 202312 financing round Series C totalling $101m incl existing + co-investor HBM Healthcare Investments |
2023-12-05 |
| Odyssey Therapeutics–SEVERAL: investment, 202312 financing round Series C $101m led by Ascenta Capital |
2023-12-05 |
| Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche |
2023-12-04 |
| WMT AG–FS Life Science Investment: investment, 202311 investment by FS Investment in WMT as part of current bridge financing |
2023-11-28 |
| WMT AG–High-Tech Gründerfonds: investment, 202311 existent HTGF is existing investor in WMT |
2023-11-28 |
| Evomedis–MC Services: public relations, 202311 service existent by MC Services |
2023-11-23 |
| T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF430m by Boehringer Ingelheim |
2023-11-22 |
| Evolva–Lallemand: investment, 202311– acquisition of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG |
2023-11-21 |
| RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF |
2023-11-21 |
| RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains |
2023-11-21 |
| Roche–Nvidia: AI-based drug r+d, 202311– collab strategic alliance multi-year of Genentech with Nvidia using Nvidia DGX Cloud + Nvidia BioNemo |
2023-11-21 |
| NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital |
2023-11-15 |
| Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise |
2023-11-14 |
| Nouscom–5AM Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor 5AM Ventures |
2023-11-14 |
| Nouscom–Andera Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Andera Partners |
2023-11-14 |
| Nouscom–EQT: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor EQT Life Sciences |
2023-11-14 |
| Nouscom–France (govt): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Bpifrance InnoBio 2 Fund |
2023-11-14 |
| Nouscom–Indaco Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Indaco Venture Partners |
2023-11-14 |
| Nouscom–Merck (DE): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor M Ventures |
2023-11-14 |
| Nouscom–Panakès Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Panakès Partners |
2023-11-14 |
| Nouscom–Revelation Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Relevation Partners |
2023-11-14 |
| Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures |
2023-11-14 |
| Nouscom–Versant Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor Versant Ventures |
2023-11-14 |
| Nouscom–XGen Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Xgen Ventures |
2023-11-14 |
| Novartis–GenScript: CAR-T cell therapies, 202311– license excl ww $100m upfront + $1.01b milestones + royalties for DLL CAR-Ts Legend Biotech |
2023-11-13 |
| Insempra–Germany (govt): grant, 202311–202610 innvoation grant €1.5m from SPRIND to advance BioTreasure prototype |
2023-11-10 |
| Valanx Biotech–Niederösterreich (govt): investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor TE |
2023-11-07 |
| Valanx Biotech–SEVERAL: investment, 202311 growth financing round €2.3m incl equity + public funding led by SkyGene |
2023-11-07 |
| Valanx Biotech–SkyGene: investment, 202311 growth financing round totalling €2.3m in equity + public funding incl new + lead investor SkyGene |
2023-11-07 |
| Valanx Biotech–SOSV: investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor SOSV |
2023-11-07 |
| Valanx Biotech–Xista Science Ventures: investment, 202311 growth financing round totalling €2.3m equity + public funding incl existing investor Xista |
2023-11-07 |
| HeartBeat.bio–SEVERAL: investment, 202311 financing round pre-Series A €4.5m with i&i Biotech Fund + Invest AG + aws + Tensor Ventures |
2023-11-02 |
| Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV |
2023-11-02 |
| Cambrium–Essential Capital: investment, 202311 seed financing round totalling €8m incl lead investor Essential Capital |
2023-11-01 |
| Cambrium–Hof Capital: investment, 202311 seed financing round totalling €8m incl co-investor Hof Capital |
2023-11-01 |
| Cambrium–Merantix: investment, 202311 existing investor Merantix with approx €3m invested? |
2023-11-01 |
| Cambrium–SEVERAL: investment, 202311 seed financing round €8m led by Essential Capital |
2023-11-01 |
| Cambrium–SNR: investment, 202311 seed financing round totalling €8m incl co-investor SNR |
2023-11-01 |
| Cambrium–Valor Equity Partners: investment, 202311 seed financing round totalling €8m incl co-investor Valor Equity Partners |
2023-11-01 |
| LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical |
2023-11-01 |
| MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets |
2023-10-30 |
| Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China |
2023-10-30 |
| CMBlu Energy–STRABAG: investment, 202310 equity investment €100m in connection with preferred partnership agreement |
2023-10-23 |
| FarmInsect–Bavaria (govt): investment, 202310 financing round Series A totalling €8m incl existing + co-investor Bayern Kapital |
2023-10-23 |
| FarmInsect–EU (govt): investment, 202310 financing round Series A totalling €8m incl new + co-investor EIC Fund |
2023-10-23 |
| FarmInsect–High-Tech Gründerfonds: investment, 202310 financing round Series A totalling €8m incl existing + co-investor HTGF |
2023-10-23 |
| FarmInsect–Minderoo Foundation: investment, 202310 financing round Series A totalling €8m incl new + co-investor MF Strategic Impact Fund |
2023-10-23 |
| FarmInsect–Sandwater: investment, 202310 financing round Series A totalling €8m incl new + lead investor Sandwater |
2023-10-23 |
| FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater |
2023-10-23 |
| FarmInsect–TU Munich: investment, 202310 financing round Series A totalling €8m incl existing + co-investor UnternehmerTUM Funding for Innovators |
2023-10-23 |
| STRABAG––CMBlu Energy: energy storage solutions, 202310– strategic collab preferred supplier agreement for SolidFlow batteries |
2023-10-23 |
| Biotech Austria–MC Services: public relations, 202310 service existent by MC Services |
2023-10-17 |
| BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC |
2023-10-12 |
| Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network |
2023-10-11 |
| AstronauTx–SEVERAL: investment, 202310 financing round Series A £48m led by Novartis Venture Fund |
2023-10-09 |
| LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund |
2023-10-09 |
| United Kingdom (govt)–Siemens: PET/CT scanner, 202310–202304 supply 2 Biograph Vision Quadra PET/CT scanners by Siemens Healthineers to NPIP |
2023-10-05 |
| MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker |
2023-10-04 |
| Orakl Oncology–SEVERAL: investment, 202310 financing round €3m led by Speedinvest with HCVC + Verve Ventures |
2023-10-04 |
| Point Biopharma–Lilly: investment, 202310–202312 cash tender offer $1.4b by Lilly at $12.5/share |
2023-10-03 |
| Kranus Health–A Round Capital: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor A Round |
2023-10-02 |
| Kranus Health–CSS (CH): investment, 202310 financing round Series A expansion totalling approx $8.5m incl new + co-lead investor SwissHealth Ventures |
2023-10-02 |
| Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF |
2023-10-02 |
| Kranus Health–Karista: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-lead investor Karista |
2023-10-02 |
| Kranus Health–SEVERAL: investment, 202310 financing round Series A expansion approx $8.5m bringing total Series A to $15m |
2023-10-02 |
| Kranus Health–Wenvest: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor Wenvest |
2023-10-02 |
| Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd |
2023-10-02 |
| AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech |
2023-10-01 |
| MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m |
2023-10-01 |
| Alentis Therapeutics–Kyan Technologies: drug discovery technology, 202309– collab using Optim.AI + PD3D technologies for Claudin-1 expression research |
2023-09-29 |
| Nagi Bioscience–Excellis: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-investor Excellis Holding |
2023-09-28 |
| Nagi Bioscience–imec: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor imec.xpand |
2023-09-28 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 44 45 46 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
